Immune Reactivity Following CD40L Blockade: Role in Autoimmune Glomerulonephritis in Susceptible Recipients

References

• Clark L. B., Foy T. M., Noelle R. J. CD40 and its ligand. Adv. Immunol. 1996; 63: 43–78
   PubMed Web of Science ®Google Scholar
• Durie F. H., Foy T. M., Masters S. R., Laman J. D., Noelle R. J. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol. Today 1994; 15: 406–410
   PubMedGoogle Scholar
• Van den Eertwegh A. J.M., Noelle R. F., Roy M., Shepherd D. M., Aruffo A., Ledbetter J. A., et al. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions. J. Exp. Med. 1993; 178: 1555–1565
   PubMed Web of Science ®Google Scholar
• Foy T. M., Laman J. D., Ledbetter J. A., Aruffo A., Claassen E., Noelle R. J. gp-39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J. Exp. Med. 1994; 180: 157–165
   PubMed Web of Science ®Google Scholar
• Noelle R. J., Roy M., Shepherd D. M., Stamenkovic I., Ledbetter J. A., Aruffo A. A.A. 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc. Natl. Acad. Sci. USA 1992; 89: 6550–6554
   PubMed Web of Science ®Google Scholar
• Aruffo A., Farrington M., Hollenbaugh D., Li X., Nonoyama A., Nonoyama S., et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linded hyper-IgM syndrome. Cell 1993; 72: 291–300
   PubMed Web of Science ®Google Scholar
• Xu J., Foy T. M., Laman J. D., Elliott E. A., Dunn J. J., Waldschmidt T. J., et al. Mice deficient for the CD40 ligand. Immunity 1994; 1: 423–431
   PubMed Web of Science ®Google Scholar
• Samoilova E. B., Horton J. L., Zhang H. D., Chen Y. H. CD40L blockade prevents autoimmune encephalomyelitis and hampers Thl but not Th2 pathway of T-cell differentiation. J. Molec. Med. 1997; 75: 603–608
   PubMed Web of Science ®Google Scholar
• Griggs N. D., Agersborg S. S., Noelle R. J., Ledbetter J. A., Linsley P. S., Tung K. S.K. The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells. J. Exp. Med. 1996; 183: 801–810
   PubMed Web of Science ®Google Scholar
• Gerritse K., Laman J. D., Noelle R. J., Aruffo A., Boersma J. A., Boersma W. J., et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. USA 1996; 93: 2499–2504
   PubMed Web of Science ®Google Scholar
• Carayanniotis G., Masters S. R., Noelle R. J. Suppression of murine thyroiditis via blockade of the CD40-CD40L interaction. Immunology 1997; 90: 421–426
   PubMed Web of Science ®Google Scholar
• Durie F. H., Aruffo A., Ledbetter J., Crassi K. M., Fast W. R., Fast L. D., et al. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J. Clin. Invest. 1994; 94: 1333–1338
   PubMed Web of Science ®Google Scholar
• Hancock W. W., Sayegh M. H., Zheng X. G., Peach R., Linsley P. S., Turka L. A. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc. Natl. Acad Sci. USA 1996
   Web of Science ®Google Scholar
• Early G. S., Zhao W., Burns C. M. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand Black × New Zealand White mice. J. Immunol. 1996; 157: 3159–3164
   PubMed Web of Science ®Google Scholar
• Mohan C., Shi Y., Laman J. D., Datta S. K. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol. 1995; 154: 1470–1480
   PubMed Web of Science ®Google Scholar
• Peng S. L., McNiff J. M., Madaio M. P., Ma J., Owen M. J., Flavell R. A., et al. αβ T cell regulation and CD40 ligand dependence in murine systemic autoimmunity. J. Immunol. 1997; 158: 2464–2470
   PubMed Web of Science ®Google Scholar
• Gleichmann E., Gleichmann H., Wilke W. Auto-immunization and lymphomagenesis in parent-F1 combinations differing at the major histocompatibility complex: Model for spontaneous disease caused by altered self-antigens?. Transplant Rev. 1976; 31: 156–22
   PubMed Web of Science ®Google Scholar
• Gleichmann E., Pals S. T., Rolink A. G., Radaszkiewicz T., Gleichmann H. Graft-versus-host reactions: clues to the etiopathology of a spectrum of immunological diseases. Immunol. Today 1984; 5: 324–332
   PubMedGoogle Scholar
• Via C. S., Shearer G. M. T cell interactions in autoimmunity: insights from a murine model of graft-versus-host disease. Immunol. Today. 1988; 9: 207–213
   PubMedGoogle Scholar
• Moser M., Mizuochi T., Sharrow S. O., Singer A., Shearer G. M. Graft-vs-host reaction limited to a class II MHC difference results in a selective deficiency L3T4+ but not in Lyt-2+ T helper cell function. J. Immunol. 1987; 138: 1355–1362
   PubMed Web of Science ®Google Scholar
• Via C. S., Sharrow S. O., Shearer G. M. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-versus-host disease. J. Immunol. 1987; 139: 1840–1849
   PubMed Web of Science ®Google Scholar
• Gleichmann E., VanElven E. H., Van der Veen J. P.W. A systemic lupus erythematosus (SLE)-like di in mice induced by abnormal T-B cell cooperation. Preferential formation of autoantibodies characteristic of SLE. Eur. J. Immunol. 1982; 12: 152–159
   PubMed Web of Science ®Google Scholar
• Rolink A. G., Radaszkiewicz T., Melchers F. The autoantigen-binding B cell repertoires of normal and of chronically graft-versus-host-diseased mice. J. Exp. Med. 1987; 165: 1675–1687
   PubMed Web of Science ®Google Scholar
• Van der Veen F., Rolink A. G., Gleichmann E. Diseases caused by reactions of T lymphocytes to incompatible structures of the major histocompatibility complex IV. Autoantibodies to nuclear antigens. Clin. Exp. Immunol. 1981; 46: 589–596
   PubMed Web of Science ®Google Scholar
• Van Rappard-Van der Veen F. M., Radaszkiewicz T., Terraneo L., Gleichmann E. Attempts at standardization of lupus-like graft-vs-host disease: Inadvertent repopulation by DBA/2 spleen cells of H-2-different nonirradiated F1 mice. J. Immunol. 1983; 130: 2693–2701
   PubMed Web of Science ®Google Scholar
• Rolink A. G., Gleichmann H., Gleichmann E. Diseases caused by reactions of T lymphocytes to incompatible structures of the major histocompatibility complex V11. Immune-complex glomerulonephritis. J. Immunol. 1983; 130: 209–215
   PubMed Web of Science ®Google Scholar
• Coligan J. E., Kruisbeek A. M., Margulies D. H., Shevach E. M., Strober W. Current Protocols in- Immunology. John Wiley & Sons, New York 1994
   Google Scholar
• Madaio M. P., Carlson J., Cataldo J., Ucci A., Migliorine P., Pankewycz O. Murine monoclonal anti-DNA antibodies bind directly to glomerular antigens and form immune deposits. J. Immunol. 1987; 138: 2883–2894
   PubMed Web of Science ®Google Scholar
• Sayegh M. H., Akalin E., Hancock W. W., Russell M. E., Carpenter C. B., Linsley P. S., et al. CD28-B7 blockade after alloantigneic challenge in vivo inhibits Thl cytokines but spares Th2. J. Exp. Med. 1995; 181: 1869–1874
   PubMed Web of Science ®Google Scholar
• Armitage P., Berry G. Statistical Methods in Medical Research. Blackwell Scientific Publication, Boston 1987
   Google Scholar
• Biancone L., Andres G., Ahn H., DeMartino C., Stamenkovic I. Inhibition of the CD40-CD40 ligand pathway prevents murine membranous glomerulonephritis. Kid. Int. 1995; 48: 458–468
   PubMed Web of Science ®Google Scholar
• Durie R. H., Fava R. A., Foy T. M., Aruffo A., Noelle J. A., Noelle R. J. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993; 261: 1328–1330
   PubMed Web of Science ®Google Scholar
• Balasa B., Krahl T., Patsone G., Lee J., Tisch R., McDevitt H. O., et al. CD40 ligand -CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J. Immunol. 1997; 159: 4620–4627
   PubMed Web of Science ®Google Scholar
• Vance B. A., Kelly C. J. Proliferation of a nephrito-genic T cell clone is inhibited by an antibody which blocks CD40-CD40 ligand interactions. J. Am. Soc. Nephrol. 1994; 5: 772
   Web of Science ®Google Scholar
• Parker D. C., Greiner D. L., Phillips N. E., Appel M. C., Steele A. W., Durie F. H., et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc. Natl. Acad. Sci. USA 1995; 92: 9560–9564
   PubMed Web of Science ®Google Scholar
• Ozaki M. E., Karlsson L., Peterson P. A., Webb S. R. Antigen specificity of dual reactive T hybridomas determines the requirement for CD40 ligand-CD40 interactions. J. Immunol. 1997; 159: 214–221
   PubMed Web of Science ®Google Scholar
• De Wit D., Van Mechelen M., Zanin C., Velu J. M., Gerarg C., et al. Preferential activation of Th2 cells in chronic graft-versus-host reaction. J. Immunol. 1993; 150: 361–366
   PubMed Web of Science ®Google Scholar
• Meyers C. M., Tomaszewski J. E., Glass J. D., Chen C. W. The nephritogenic T cell response in murine chronic graft-vs-host disease. J. Immunol. 1998; 161: 5321–5330
   PubMed Web of Science ®Google Scholar
• Perrin P. J., Scott D., Quigley L., Alert P. S., Feder O., Gray G. S., et al. Role of 87: CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J. Immunol. 1995; 154: 1481–1490
   PubMed Web of Science ®Google Scholar
• Kirk A. D., Harlan D. M., Armstrong N. N., Davis T. A., Dong Y. C., Gray G. S., et al. CTLA4-1g and anti-CD40 ligand prevent renal-allograft rejectoin in primates. Proc. Natl. Acad. Sci. USA 1997; 94: 8789–8794
   PubMed Web of Science ®Google Scholar
• Bolling S. F., Lin H., Wei R. Q., Turka L. A. Preventing allograft rejection with CTLA4-1g: effect of donor-specific transfusion, route, or timing. J. Heart & Lung Transplant 1996; 15: 928–935
   PubMed Web of Science ®Google Scholar
• Daikh D. I., Finck B. K., Linsley P. S., Hollenbaugh D., Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J. Immunol. 1997; 159: 3104–3108
   PubMed Web of Science ®Google Scholar